A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-09-12. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: ventricularbreast cancerleftcardiomyopathysyndrome
  Phrases that lowered it: healthyparticipantsadministrationparticipantkg
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Sponsor's past trials: 1729 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 11.1% (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: 8.2% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 207 (lowers risk) · Sponsor's track record
• Blinding: none (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: 55 (lowers risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 74.5% (lowers risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design
• Disease area, psychiatry: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects NCT04492709 · started 2020 · scored riskier than 2% of active trials completed
• A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers NCT05512806 · started 2022 · scored riskier than 1% of active trials completed
• A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718 NCT04087187 · started 2019 · scored riskier than 3% of active trials completed
• A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718 Oral Suspension vs AZD5718 Immediate Release Tablet NCT02963116 · started 2016 · scored riskier than 0% of active trials completed
• A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers NCT03420092 · started 2018 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.